US FDA Chief Scientist Bumpus Will Become Principal Deputy Commissioner
When Janet Woodcock retires early next year, Namandjé Bumpus will take over as No. 2 in command at the FDA. Since joining the agency in 2022 from Johns Hopkins, her profolio has included health disparities, cosmetics, and drug review disputes.
You may also be interested in...
The FDA will go on without Janet Woodcock, but it will likely take multiple people to fill in the gaps given her breadth of institutional knowledge, interests and skill sets, former close colleagues told the Pink Sheet.
Company contends US FDA gave the committee ‘materially false and misleading information’ about ITCA 650 exenatide implant and did not focus on GLP-1 comparative claims as it seeks a hearing before the commissioner following the panel’s unanimous vote against the application.
The US FDA Commissioner acknowledged that the inspectorate has not been prepared for RWE, but as part of the revamp, a dedicated team will encourage its use “when it’s appropriate.”